ALK+ mNSCLC May Lead to Disease Progression, Including in the CNS

A crucial goal in the treatment of ALK+ mNSCLC is delaying disease progression in newly diagnosed patients for as long as possible 2,5

  • Approximately half of patients with ALK+ mNSCLC progress within 12 months on crizotinib, historically the most prescribed ALK inhibitor for first-line ALK+ mNSCLC 1,2 

Common Sites of Extra-Thoracic Metastases in Newly Diagnosed Patients in the ALEX Study 2,3 

CNS: ~39%, Lymph Nodes: ~49%, Liver: ~21%

aIdentified by IRC.
 bIdentified by Investigator.

This is an analysis of patient characteristics in a clinical trial of ALECENSA® (alectinib) and may not be representative of the entire population of patients with ALK+ mNSCLC.

Metastases in the CNS can often go undetected 6,7

Retrospective Analysis of Patients with NSCLC 8

Approximately half of lung cancer patients with CNS metastases were asymptomatic

Micrometastases can cross the blood-brain barrier and may develop into larger lesions 6,7

1L=first-line; CNS=central nervous system; IRC=Independent Review Committee; PFS=progression-free survival.

Next: Proposed Mechanism of Action

1L PFS Results

View PFS results vs crizotinib from the head-to-head ALEX trial.

View Data

CNS Efficacy in 1L ALK+ mNSCLC

Learn more about CNS efficacy with ALECENSA.

View Data

Financial Support for Patients

Learn more about ALECENSA patient and practice resources.

Learn More